ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1037
0,00%
Bitcoin
66.869,36
1,07%
Brent Oil
83,855
0,31%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Pharvaris NV (PHVS)

  7. Pharvaris NV (PHVS) Notícias

PHVS

Pharvaris NV (PHVS)

Pharvaris NV
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PHVS
DataHoraFonteTítuloCódigoCompanhia
13/05/202407:50GlobeNewswire Inc.Pharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
08/05/202417:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
08/05/202417:10GlobeNewswire Inc.Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202417:10GlobeNewswire Inc.Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202417:08GlobeNewswire Inc.Pharvaris Appoints David Nassif, J.D., as Chief Financial OfficerNASDAQ:PHVSPharvaris NV
04/04/202407:50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceNASDAQ:PHVSPharvaris NV
18/03/202407:50GlobeNewswire Inc.Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesNASDAQ:PHVSPharvaris NV
11/03/202414:51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
06/03/202418:40Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PHVSPharvaris NV
06/03/202408:50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
05/03/202408:50GlobeNewswire Inc.Pharvaris to Participate in the Leerink Global Biopharma Conference 2024NASDAQ:PHVSPharvaris NV
22/02/202408:50GlobeNewswire Inc.Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingNASDAQ:PHVSPharvaris NV
16/02/202408:50GlobeNewswire Inc.Pharvaris Announces Extraordinary Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
26/01/202408:50GlobeNewswire Inc.Pharvaris to Present at the WSAAI Annual Meeting 2024NASDAQ:PHVSPharvaris NV
22/01/202409:35Dow Jones NewsPharvaris Says FDA Lifted Clinical Hold on Application for DeucrictibantNASDAQ:PHVSPharvaris NV
22/01/202408:50GlobeNewswire Inc.Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
05/01/202408:50GlobeNewswire Inc.Pharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesNASDAQ:PHVSPharvaris NV
08/12/202320:00GlobeNewswire Inc.Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
07/12/202318:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHVSPharvaris NV
06/12/202309:08Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PHVSPharvaris NV
06/12/202309:02GlobeNewswire Inc.Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded WarrantsNASDAQ:PHVSPharvaris NV
06/12/202308:50GlobeNewswire Inc.Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
30/11/202308:50GlobeNewswire Inc.Pharvaris to Present at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
15/11/202308:50GlobeNewswire Inc.Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations OfficerNASDAQ:PHVSPharvaris NV
09/11/202313:00GlobeNewswire Inc.Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific MeetingNASDAQ:PHVSPharvaris NV
02/11/202307:50GlobeNewswire Inc.Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
30/10/202307:50GlobeNewswire Inc.Pharvaris To Present at the ACAAI 2023 Annual Scientific MeetingNASDAQ:PHVSPharvaris NV
13/10/202307:50GlobeNewswire Inc.Pharvaris To Present at the APAAACI 2023 International ConferenceNASDAQ:PHVSPharvaris NV
04/10/202308:34GlobeNewswire Inc.Pharvaris To Present at the CIIC Fall 2023 ConferenceNASDAQ:PHVSPharvaris NV
19/09/202307:50GlobeNewswire Inc.Pharvaris To Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:PHVSPharvaris NV
 Apresentando as notícias mais relevantes sobre:NASDAQ:PHVS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados